Cardiac dysfunction in patients with liver cirrhosis is strongly associated with increased serum bile acid concentrations. Here we show that excess bile acids decrease fatty acid oxidation in cardiomyocytes and can cause heart dysfunction, a cardiac syndrome that we term cholecardia. Farnesoid X receptor; Small Heterodimer Partner double knockout mice, a model for bile acid overload, display cardiac hypertrophy, bradycardia, and exercise intolerance. In addition, double knockout mice exhibit an impaired cardiac response to catecholamine challenge. Consistent with this decreased cardiac function, we show that elevated serum bile acids reduce cardiac fatty acid oxidation both in vivo and ex vivo. We find that increased bile acid levels suppress expression of proliferator-activated receptor-c coactivator 1a, a key regulator of fatty acid metabolism, and that proliferatoractivated receptor-c coactivator 1a overexpression in cardiac cells was able to rescue the bile acid-mediated reduction in fatty acid oxidation genes. Importantly, intestinal bile acid sequestration with cholestyramine was sufficient to reverse the observed heart dysfunction in the double knockout mice. Conclusions: Decreased proliferator-activated receptor-c coactivator 1a expression contributes to the metabolic dysfunction in cholecardia so that reducing serum bile acid concentrations may be beneficial against the metabolic and pathological changes in the heart. (HEPATOLOGY 2017;65:189-201).
C irrhotic cardiomyopathy is a severe cardiovascular condition characterized by rhythm abnormalities, poor contractility, and dysfunction. (1) Patients with this pathology have delayed recovery after surgical procedures and exhibit increased fatality. (2) (3) (4) (5) Cirrhotic cardiomyopathy occurs in >50% of patients with end-stage liver diseases; however, the heart dysfunctions are reversed upon liver transplant. (6) These data suggest that the cardiomyopathy is secondary to the liver dysfunction. Despite its clinical significance, there is no treatment currently available for this heart dysfunction as the mechanism(s) that contributes to its pathogenesis remains poorly understood.
Elevated serum bile acids have long been speculated to cause cirrhotic cardiomyopathy. (7, 8) In fact, bile was first observed to mediate cardiotoxicity almost a century ago. (9) Increase in bile acids has been shown to reduce heart rate and contractility, (10, 11) with recent findings indicating that high bile acid levels are linked to arrhythmias in adults as well as fetuses of mothers with obstetric cholestasis. (12, 13) Based on these strong associative findings, we propose the term cholecardia to describe a syndrome in which pathological levels of bile acids induce cardiomyopathy.
In the present study, we explored the mechanisms that contribute to cholecardia by characterizing the direct effects of bile acids on the heart using an in vivo mouse model, ex vivo heart perfusions, as well as in vitro primary cardiomyocyte cultures and a cardiac cell line. We hypothesized that pathological concentrations of bile acids induce functional, metabolic, and molecular alterations in the heart and that reducing serum bile acid pools will reverse cholecardia.
Materials and Methods

ANIMAL MODELS
The generation of farnesoid X receptor (Fxr) knockout (FXRKO), small heterodimer partner (Shp) knockout (SHPKO) and Fxr;Shp double KO (DKO) mice has been described. (14) C57BL/6 wild-type (WT) male mice were purchased from Harlan (Indianapolis, IN). Mice were housed on a standard 12-hour light/dark cycle and fed normal chow and water ad libitum. To reduce circulating bile acid levels, DKO mice were fed a 2% cholestyramine (CHR)-enriched diet for 5 weeks. All experiments were carried out on mice 3-5 months old as outlined in the Guide for the Care and Use of Laboratory Animals (National Institutes of Health publication 86-23, revised 1985) and approved by the Institutional Animal Care and Use Committee at Baylor College of Medicine as well as the University of Illinois at Urbana-Champaign.
ELECTROCARDIOGRAPIC AND ECHOCARDIOGRAPHIC STUDIES
Continuous M-mode electrocardiograms were recorded noninvasively in mice (n 5 6, age 4-5 months) using the EC Genie system (Mouse Systems Inc., Quincy, MA) as described. (15) Twodimensional echocardiography was performed in the Mouse Phenotyping Core at Baylor College of Medicine and at the Beckman Institute, University of Illinois, Urbana-Champaign on sedated mice (Vevo Digital Scanner; VisualSonic Inc., Toronto, CA). To evaluate the acute in vivo effect of bile acid overload, WT mice were injected with a single dose of either taurocholic acid (TCA, 100 mg/kg) or lithocholic acid (100 mg/kg) dissolved in corn oil for 4 days or corn oil intraperitoneally prior to echocardiography.
TREADMILL EXERCISE PERFORMANCE TEST
DKO mice were challenged with acute submaximal stress in the form of exercise on a treadmill as described. (15) WT and DKO mice (n 5 6 per group) were first allowed to acclimatize on a treadmill for 5-10 minutes and then made to run on it with a 10% incline at a speed of 2 m/minute. Speed was gradually increased by 2 m/minute every 2 minutes to a maximal speed of 15 m/minute. The exercise was terminated when the mouse became sedentary on the active electric grid at the end of the treadmill for more than 15 seconds for at least two occasions.
ARTICLE INFORMATION:
CATECHOLAMINE CHALLENGE AND STRESS ECHOCARDIOGRAPHY
To evaluate the effects of catecholamine on the hearts, WT and DKO mice (n 5 6 per group) were anesthetized and injected with a single dose of isoprenaline intraperitoneally (20 lg/kg; SigmaAldrich, St. Louis, MO). Cardiac parameters were evaluated by echocardiography both preinjection and postinjection.
TRANSVERSE AORTIC CONSTRICTION
To determine the response to chronic pressure overload, both WT and DKO mice were subjected to transverse aortic constriction. (16) Prior to isofluraneinduced anesthesia, each mouse received buprenorphine (0.6 mg/kg) subcutaneously. An incision was made through the ventral chest skin to the mid-thorax and between the right innominate and left carotid arteries. An aortic constriction was placed by tying a 6-0 black-braided nonabsorbable silk suture against a 3-mm length of a 27-gauge needle. The tightness of the 0.3-mm constriction was verified 7 days postbandaging using a carotid Doppler ultrasound. Contractile function was evaluated every 2 weeks by echocardiography for a period of 8 weeks.
LANGENDORFF PERFUSION EXPERIMENTS
The retrograde constant flow Langendorff perfusion method was used as described (17, 18) to evaluate contractility, glucose, and fatty acid (oleate) oxidation rates in isolated beating hearts of DKO and WT mice. Further, the effect of a high dose of TCA (500 lmol/L) was also evaluated on WT hearts. In brief, the hearts were perfused, and physiological parameters such as heart rate (cycle beats) and contractility (cycle amplitude) were measured in real time for over 15 minutes on the isolated hearts. To measure glucose and oleate oxidation rates, the perfusate Krebs-Henseleit buffer (8 mM glucose, 10 lU/mL insulin, 1.2 mM sodium oleate conjugated to 3% w/v bovine serum albumin tracer amounts of [U- 14 
ANALYSIS OF TOTAL SERUM BILE ACID LEVELS AND COMPOSITION
Total serum bile acids were measured using a colorimetric BQ assay kit (BQ Kits, Inc., San Diego, CA) according to the manufacturer's protocol. Pooled serum from either WT or DKO mice (n 5 5-7 mice) was analyzed for individual bile acid contents using a liquid chromatographic-mass spectrometric method in the Metabolomics Core at Baylor College of Medicine. A Waters (Milford, MA) Acquity UPLC BEH C18 column was used for analysis. All bile acids were detected in negative mode. LZeatine was spiked into each sample as an internal standard.
IMMUNOBLOTTING
Proteins were extracted from homogenized hearts using standard procedures, (19) and the concentration was measured using the Pierce BCA kit (Thermo Scientific, Rockford, IL). After gel electrophoresis and transfer, the blots were probed for expression of various proteins with specific antibodies, as described. (15) Equal protein loading was confirmed by TATA binding protein (TBP). The results were analyzed by densitometry using Kodak software and are reported as fold change compared to control hearts.
QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION
Total RNA was isolated from snap-frozen hearts (n 5 5-6 per group) and cultured HL-1 cells (n 5 4) using TRIzol (Invitrogen, Grand Island, NY) and subjected to SYBR green-based quantitative real-time reverse-transcription polymerase chain reaction using mouse-specific primer sets, listed in Supporting Table  S2 . Relative RNA expression was calculated by the delta-delta cycle threshold method, and transcript levels were normalized to 36B4 or 18S as internal controls.
24 hours and subsequently processed. Heart sections (5 lm thick) were cut, deparaffinized, and stained with hematoxylin and eosin as well as Masson's trichrome using standard histological protocols.
QUANTIFICATION OF CARDIOMYOCYTE SIZE USING WHEAT GERM AGGLUTININ STAINING
Heart sections were deparaffinized (n 5 2-3 mice/group) and incubated with 10 lg wheat germ agglutinin (WGA)-Alexa Fluor 488 (Thermo Fisher Scientific) for 2 hours at room temperature, followed by two washes with 13 phosphatebuffered saline. The slides were then incubated with Molecular probe NucBlue for 30 minutes at room temperature and coverslipped. Eight to 10 fields per section per mouse were quantitated using ImageJ WGA macro (http://www2.le.ac.uk/colleges/medbiopsych/facilities-and-services/cbs/lite/aif/ software-1/imagej-macros#WGA).
NEONATAL MOUSE CARDIOMYOCYTE CULTURE
Cardiomyocytes were isolated from 2-day-old to 3-day-old neonatal WT mouse pups as described. (15) Isolated cardiomyocytes (5 3 10 5 cells/well) were incubated with vehicle (dimethyl sulfoxide) or chenodeoxycholic acid (CDCA, 100 lM) in a six-well plate. After 4 hours, cells were harvested for RNA expression by quantitative real-time reverse-transcription polymerase chain reaction analysis. Each experiment was performed in duplicate and repeated three times (n 5 3). For each set of treatments, cardiomyocytes were isolated and pooled from 12-15 neonatal hearts.
PROLIFERATOR-ACTIVATED RECEPTOR-c COACTIVATOR 1a OVEREXPRESSION STUDIES
The cardiac HL-1 cell line was cultured as described. (20) Proliferator-activated receptor-c coactivator 1a (Pgc1a) expression plasmid was obtained as a gift from Dr. J.K. Kemper's laboratory at the University of Illinois, Urbana-Champaign. Approximately 80% confluent HL-1 cells were transfected with 50 ng of the Pgc1a gene containing pCDNA3.1 plasmid or empty vector using TransIT 2020 reagent. Following 24 hours of transfection, the cells were treated with 100 lM CDCA or Vehicle (dimethyl sulfoxide) for 4 hours and harvested for RNA studies.
STATISTICAL ANALYSIS
Data are presented as mean 6 standard error of the mean (as specified in the figure legends). Data between two groups (DKO and WT) were compared using the unpaired t test as well as the nonparametric MannWhitney. Preintervention and postintervention WT or DKO and DKO1CHR comparisons were performed using one-way analysis of variance, followed by Bonferroni or Newman Keuls post hoc test. Pgc1a overexpression analyses were performed using multiple t tests and two-way analysis of variance, followed by a Bonferroni post hoc test. Ex vivo perfusion parameters and in vitro bile acid incubation experiments were evaluated using the nonparametric Mann-Whitney test. Comparisons between WT and either FXRKO or SHPKO mice were analyzed using the Student t test. All statistical analyses were done using Prism (GraphPad, San Diego, CA). P < 0.05 was selected as the level of significance.
Results
We previously described mice in which two key nuclear receptors responsible for maintaining bile acid homeostasis, Fxr and Shp, are deleted. (14) These DKO mice demonstrate excessive liver injury and accumulate high levels of circulating bile acids along with increases in alanine aminotransferase and aspartate aminotransferase liver enzymes and, thus, are an excellent model of cholestatic liver disease (Supporting Fig.  S1A,B) .
DKO MICE MIMIC CIRRHOTIC CARDIOMYOPATHY WITH CARDIAC HYPERTROPHY AND FUNCTIONAL DEFECTS
Compared to adult WT mice, DKO mice showed increased heart weight to tibial length ratio (Fig.  1A) . In addition, WGA staining of the cell membrane revealed an increase in cardiomyocyte size (Fig. 1B) . However, hematoxylin and eosin as well as Masson's trichrome staining did not show any signs of fibrosis in the heart (Supporting Fig. S1C,  D) . We observed a robust induction of the core cytoskeletal proteins a/b actin and a/b tubulin (Fig.  1C ) that was consistent with the observed myocardial dysfunction in DKO hearts. (21) Upon twodimensional echocardiographic evaluation, (22) DKO mice displayed abnormal M-mode with decreased left ventricular internal diameter (LVID) in diastole as well as in systole (Fig. 1D) . Despite compensatory increases in LV shortening and ejection fraction, DKO mice showed lower cardiac output than WT mice (Fig. 1E) . Furthermore, DKO mice showed prolonged QTc and PR intervals on echocardiography (Fig. 1E) , which is specifically observed in human cirrhotic cardiomyopathy and strongly correlates with the observed mortality in adults and children with cirrhosis. (23, 24) DKO hearts also displayed bradycardia, increased myosin heavy chain b isoform (b-MyH7) expression along with FIG. 1. DKO mice show cardiac hypertrophy and abnormal cardiovascular parameters at baseline. (A) Compared to WT, DKO mice exhibited increased heart weight to tibial length ratio. (B) DKO cardiomyocytes were larger as quantified by WGA staining (n 5 2-3 mice/group, ***P < 0.001). (C) Cardiac cytoskeletal proteins a/b-actin and a/b-tubulin were induced in DKO hearts as seen by western blots. TATA binding protein was used as the loading control. (D) M-mode echocardiographic images of the LV displayed reduction in LVID in both diastole and systole in DKO mice. (E) Ejection fraction, shortening fraction, and QTc and PR intervals were increased in DKO mice, whereas cardiac output was reduced. (F) Enzyme-linked immunosorbent assay for cardiac troponin T showed induction in DKO mice (n 5 6-12 mice/group; *P < 0.05, **P < 0.001 compared to WT mice, mean 6 standard error of the mean). Abbreviations: CO, cardiac output; EF, ejection fraction; FS, shortening fraction; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; TBP, TATA binding protein; TL, tibial length. robust activation of AKT (Ser473 phosphorylation) and c-Jun N-terminal kinase (Thr183/Tyr185 phosphorylation), and apoptotic pathways (Supporting Fig. S2 ), consistent with pathological cardiac remodeling. (25, 26) DKO mice also showed a significant elevation in serum cardiac troponin-2 levels (Fig. 1F) , suggesting myocardial injury. (27) These data clearly indicate that DKO mice suffer from cardiac stress and mirror clinical symptoms of cirrhotic cardiomyopathy.
DKO MICE DISPLAY IMPAIRED RESPONSE TO EXOGENOUS CARDIAC STRESSORS
Patients with cirrhotic cardiomyopathy have poor response to exercise-induced stress (28) and catecholamines. (6) As expected, DKO mice had significantly decreased performance in terms of both distance and time on the treadmill exercise test compared to WT mice ( Fig. 2A,B) . Upon isoprenaline challenge, DKO mice took twice the amount of time to achieve the peak increase in heart rate than the controls (Fig. 2C) . Moreover, this peak heart rate was slightly blunted in the DKO mice (Fig. 2D ) along with reduced response in the ejection fraction (Fig. 2E) . The increase in shortening fraction observed in the DKO mice pre-isoprenaline treatment was attenuated postinjection, indicating repressed b-adrenergic signaling (Fig. 2F) . Finally, we examined the ability of DKO hearts to handle pressure overload by performing transverse aortic constriction. Though the decrease in shortening fraction was comparable between DKO and WT mice, the DKO mice showed a significant decrease in ejection fraction and an increase in heart weight in response to transverse aortic constriction (Supporting Fig. S2E,F) .
DKO MICE EXHIBIT A SWITCH TO THE FETAL METABOLIC GENE PROGRAM IN THE HEART
The metabolic switch from fatty acid to glucose utilization in a stressed heart involves reactivation of the fetal gene program. (29) In DKO mice, we found that the major regulators of fatty acid metabolism, Pgc1a and peroxisome proliferator-activated receptor alpha (Ppara),
2. DKO mice demonstrate exercise intolerance and catecholamine insensitivity. WT mice were able to run a greater distance (meters) (A) and for a longer time (minutes) on the treadmill (B) compared to DKO mice. Upon isoprenaline challenge, DKO mice took longer to reach peak heart rate (C,D) and displayed lower changes in ejection fraction and shortening fraction (E,F). (n 5 5-6/ group; *P < 0.05, **P < 0.01 compared to WT animals, mean 6 standard error of the mean). Abbreviations: EF, ejection fraction; FS, shortening fraction.
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were significantly down-regulated ( Fig. 3A ; Supporting  Fig. S3A ). Consistent with this, expression of a panel of PGC1a target genes, including mitochondrial carnitine palmitoyl transferase-1/2 (mCpt1/2); estrogen-related receptor alpha/gamma; Tfam, nuclear respiratory factor-1 and 2 (Nrf-1/2) ( Fig. 3B,C; Supporting Fig. S3 ) were robustly reduced in DKO hearts compared to WT mice. Additionally, we observed suppression of pyruvate dehydrogenase kinase 4 (Pdk4), a known inhibitor of glucose oxidation (Fig. 3D ). These data show that DKO hearts switch their substrate use from fat to glucose oxidation, indicating a stress response. To test whether the gene expression changes functionally reflect a metabolic switch in DKO hearts, we used ex vivo Langendorff heart perfusions. DKO hearts demonstrated a decrease in oleate oxidation coupled with subsequent increase in glucose oxidation within 15 minutes of ex vivo analysis (Fig. 3E,F) . We conclude that the decreased functional capacity in DKO hearts is linked to the metabolic alteration.
INDIVIDUAL LOSS OF NEITHER FXR NOR SHP PHENOCOPIES DKO HEARTS
Recently, roles for FXR in myocardial injury (30) and SHP in cardiac hypertrophy (31) have been identified. Hence, we examined whether deletion of Fxr or Shp alone led to the altered metabolic gene expression profile in DKO mice. To do this, we carefully analyzed the expression of fatty acid and glucose regulator genes in FXRKO and SHPKO hearts and compared them to WT animals. Interestingly, the reduction in expression of metabolic genes including Pgc1a, Ppara, and their downstream targets readily seen in the DKO hearts was not observed in the single knockouts. In fact, Ppara, m-Cpt2, and Pdk4 expression were up-regulated in FXRKO mice (Supporting Fig. S4A-E) . In SHPKO hearts, there was a modest reduction in m-Cpt1 and Pdk4 expression (Supporting Fig. S5A-E) . The echocardiographic findings corroborated the gene expression data in that   FIG. 3 . Metabolic switch occurs in DKO hearts. Compared to WT, quantitative real-time reverse-transcription polymerase chain reaction analysis of DKO hearts revealed significant down-regulation of FAO genes Pgc1a and m-Cpt1/2 (A-C). Additionally, the regulator of glucose oxidation Pdk4 was altered in DKO hearts (D). All gene expression data were normalized to 36b4. (E,F) Line diagram showed a switch from oleate to glucose oxidation in the DKO whole hearts mounted ex vivo on the Langendorff apparatus (n 5 5/group; *P < 0.05, **P < 0.01, ****P < 0.001 compared to WT mice, mean 6 standard error of the mean).
no contractile abnormality was observed in FXRKO mice or SHPKO mice, except for a slight reduction in heart rate in the latter compared to their WT littermates (Supporting Figs. 4F and 5F).
BILE ACIDS ARE SUFFICIENT TO MIMIC THE HEART DYSFUNCTION PHENOTYPE OBSERVED IN DKO MICE
To determine the effect of acutely increased circulating bile acids on the heart, we injected WT mice with the bile acids, TCA, LCA, or vehicle and performed preinjection and postinjection electrocardiography and echocardiography. Bile acid injections induced significant bradycardia in naive WT mice (Supporting Fig.  S6A ). Acute exposure to bile acids did not change echocardiographic parameters but modestly reduced the LV diameter (Supporting Fig. S6B,C) .
We next examined whether acute bile acid challenge alters the metabolic preference in the heart. Using the ex vivo Langendorff method, WT hearts were perfused with TCA. Compared to vehicle, TCA perfused hearts showed a rapid 50% decrease in heart rate and cycle amplitude (myocardial force of contractility) (Supporting Fig. S6D,E) . This was accompanied by a dramatic 50% reduction in oleate oxidation within 15 minutes upon TCA perfusion (Supporting Fig. S6F ). These data demonstrate that excess bile acids directly cause metabolic and functional changes in the heart. To identify the mechanisms by which bile acids cause metabolic alterations, we performed in vitro studies using both the primary mouse cardiomyocyte culture and the well-established cardiac HL-1 cell line. (20) We treated cardiomyocytes with the pathological concentration of CDCA observed during liver diseases. (32) Remarkably, the high dose of CDCA dramatically suppressed fatty acid oxidation (FAO) regulators such as Pgc1a, m-Cpt1, Nrf-1, Nrf-2, and Tfam (Fig. 4A-D) in primary cardiomyocytes, whereas bile acid treatment did not alter m-Cpt2 (Fig. 4B) levels. Consistent with the data seen in DKO mice, Pdk4,
FIG. 4.
Bile acids are sufficient to suppress FAO genes in primary cardiomyocytes. Neonatal cardiomyocytes, incubated with CDCA (100 lM) for 4 hours, were evaluated for key genes regulating fatty acid and glucose oxidation. 18S was used as the loading control. Values are depicted as fold change to vehicle values (n 5 3 sets; *P < 0.05, **P < 0.001 compared to vehicle-treated cardiomyocytes).
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a crucial inhibitor of glucose oxidation (Fig. 4E) , was down-regulated in the cardiomyocytes in response to CDCA.
Similarly, HL1 cardiac cells displayed modest but significant down-regulation in these genes (Fig. 5) when challenged with high doses of CDCA. However, a nonpathological dose of CDCA did not induce any alterations in the metabolic gene profiles (data not shown). It is important to point out that only pathological concentrations of bile acid were able to recapitulate both the functional and molecular changes in primary cardiomyocytes and HL-1 cells, as observed in the DKO mice hearts (Figs. 3-5 ).
OVEREXPRESSION OF Pgc1a RESCUES BILE ACID-INDUCED METABOLIC ALTERATIONS IN VITRO
Hearts from Pgc1a KO mice demonstrate increased glucose oxidation and reduced FAO, highlighting that Pgc1a is a master regulator for cardiac metabolism. (33) (34) (35) Therefore, we examined if the metabolic effects of bile acids can be reversed by Pgc1a overexpression. We ectopically expressed Pgc1a in HL-1 cells, with increased levels maintained even upon CDCA incubation (Fig. 5A) . CDCA-mediated reductions in the levels of the FAO genes Ppara and m-Cpt1 as well as the glucose oxidation gene Pdk4 were derepressed upon this overexpression (Fig. 5B-D) .
DECREASING SERUM BILE ACID LEVELS COMPLETELY RESCUED CARDIAC DYSFUNCTION IN DKO MICE
To determine if pathological bile acids were directly responsible for the observed cardiac defects, we treated DKO mice with CHR, a bile acid binding resin known to reduce the circulating bile acid pool. As expected, the serum bile acid concentrations in DKO mice robustly decreased to half the original DKO concentration upon treatment with the CHR diet. This reduction is also reflected in the overall decrease in the bile acid composition (Fig. 6A) .
M-mode echocardiographic analysis revealed that CHR feeding was sufficient to restore the functional cardiac parameters in the DKO mice, including heart rate and cardiac output, to control WT levels (Fig.  6B) . Consistent with these data, LVID in both diastole and systole increased in the CHR-fed DKO compared to chow fed DKO mice (Fig. 6C) . Furthermore, these functional changes were accompanied by upregulation of FAO genes Pgc1a, m-Cpt1, and m-Cpt2 (Fig. 6D,E) . Taken together, these findings suggest that reducing circulating bile acid pools is sufficient to reverse the cardiac pathology associated with cholecardia. The overall mechanism is summarized in Fig. 6F .
Discussion
A wide array of end-stage liver diseases, including alcoholic cirrhosis, (36) chronic hepatitis B or C viral
Overexpression of Pgc1a is sufficient to reverse bile acid-mediated alteration in metabolic genes. Pgc1a was ectopically expressed in a cohort of HL-1 cells prior to CDCA treatments. The CDCA-mediated switch in metabolic genes in vitro was effectively rescued by Pgc1a overexpression. Gene expression was normalized to 36b4 (n 5 4-6; *P < 0.05 compared to vehicle, # P <0.05 ## P < 0.01 compared to CDCA-treated HL-1 cells, mean 6 standard error of the mean). Abbreviation: O.E., overexpression.
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FIG. 6.
Reduction in circulating bile acid pools reverts the observed cardiomyopathy in vivo. (A) DKO mice fed CHR exhibited a 50% decrease in serum bile acid levels compared to DKO mice on chow. Serum bile acid composition is shown as fold change to WT mice. (B) Two-dimensional echocardiographic analysis revealed normal heart rate and cardiac output in CHR-fed DKO mice.
(C) LVID in diastole and systole was restored to the WT level when DKO mice were fed CHR. (D,E) The fatty acid regulator Pgc1a and metabolic genes (m-Cpt1/2) were up-regulated in DKO1CHR hearts compared to DKO1chow mice. Gene expression was normalized to 36b4 (n 5 4-7 mice/group; *P < 0.05, **P < 0.01, ****P < 0.001 compared to WT chow; # P < 0.05, ## P < 0.01, ### P < 0.005 compared to DKO chow; mean 6 standard error of the mean). (F) Proposed schematic indicating a mechanism by which bile acid overload can induce a metabolic switch in the heart, resulting in cardiac hypertrophy and dysfunction (cholecardia). Abbreviations: BA, bile acid; CA, cholic acid; DHCA, 3a,7a-dihydroxycholestanoic acid; GHCA, glycohyocholic acid; GLCA, glycolithocholic acid; HCA, hyocholic acid; HDCA, hyodeoxycholic acid; LCA, lithocholic acid; MCA, muricholic acid; TCDCA, taurochenodeoxycholic acid; THDCA, taurohyodeoxycholic acid; TMDCA, tauromurideoxycholic acid; TUDCA, tauroursodeoxycholic acid; UDCA, ursodeoxycholic acid. infection, and nonalcoholic fatty liver disease (37) result in heart dysfunction. (1, 4, 38) However, the molecular mechanisms underlying this liver disease-dependent heart failure are not understood. Increased circulating levels of bile acids are observed in all of these cases of liver dysfunction (39) and are strongly associated with cardiomyopathy. (7, 8, 11, 12, 40) It has been shown that jaundice and/or cholestasis can impede b-adrenergic signaling and thus may lead to blunted cardiac contractility in these patients. (36) In this study we demonstrate that pathological levels of bile acids are sufficient to cause cardiac dysfunction and metabolic reprogramming (Figs. 4-6 ). We therefore propose the term cholecardia to describe the syndrome of cardiac dysfunction in response to elevated bile acid levels.
The Fxr;Shp DKO mouse is an excellent model for cholestatic liver disease, with elevated serum bile acids and enzymes alanine aminotransferase and aspartate aminotransferase (Supporting Fig. S1 ). DKO mice exhibit cholestasis from an early age and do not have acute pharmacologic and toxicologic confounders, as observed in 3,5-diethoxycarbonyl-1,4-dihydrocollidine and carbon tetrachloride models of end stage liver disease. (41, 42) One limitation of the DKO model is that it is a global, rather than a cardiomyocyte-specific, Fxr;Shp deletion. We partially addressed this limitation by conducting ex vivo and in vitro experiments focusing on direct bile acid-myocardial interactions in WT cells with intact cardiomyocyte expression of FXR and SHP. Although there are some differences between our model and cirrhosis patients (Supporting Table S1 ), DKO mice provide a functional correlation to the clinical findings seen in human cirrhotic cardiomyopathy. Hearts of cirrhosis patients show hypertrophic LV with diastolic dysfunction, prolonged QT interval, and impaired response to exercise and catecholamine-induced stress. All of these findings are phenocopied in the DKO mouse hearts, except for clinical tachycardia ( Figs. 1 and 2 ; Supporting Table S1 ). DKO mice instead exhibit bradycardia, which could be due to a direct inhibitory effect of bile acid on heart rate and rhythm, as described. (11, 43) In addition, DKO hearts show increased expression of cytoskeletal proteins along with activation of c-Jun N-terminal kinase and AKT ( Fig. 1; Supporting Fig. S2 ), indicating molecular remodeling of DKO cardiomyocytes.
There is an intricate relationship between cardiac metabolism and function. It is well known that the perturbations in cardiac metabolism can precede contractile dysfunction, progressive LV remodeling, and heart failure. (34, 44) Therefore, we examined the metabolic gene expression profile in DKO hearts and found downregulation of a key coactivator and three nuclear receptors associated with FAO (Pgc1a, Ppara, estrogenrelated receptor alpha/gamma). This reduction was reflected in decreased expression of target genes (mCpt1, m-Cpt2, Nrf-1/2, and Tfam) and decreased preference for FAO in DKO hearts ex vivo ( Fig. 3 ; Supporting Fig. S3) . (29) Moreover, the DKO heart exhibited suppression of Pdk4, a negative regulator of glucose oxidation, indicating an increase in glucose oxidation (Fig.  3) . Together these results indicate a metabolic switch from fatty acid to glucose, which can function both as a "cause" and an "effect" of cardiac stress and can explain cardiac defects seen in the DKO mice.
Next, we tested if elevated circulating levels of bile acids, which are characteristic of the DKO mouse model as well as cirrhotic and noncirrhotic liver diseases, are sufficient to induce myocardial defects. (14) It is known that high levels of bile acids are toxic to the heart (12, 32, 39) ; in particular, TCA has been directly linked to fetal arrhythmias and poor cardiomyocyte contractility. (11, 13, 40, 45) Moreover, bile acids are rapidly emerging as specialized signaling molecules, (46, 47) regulating metabolism and the function of various tissues. They signal by both the nuclear receptor FXR and the G protein-coupled receptor TGR5, both of which are expressed in the heart. (15) We found that bile acids rapidly and directly modulate heart function. WT hearts exposed to high concentrations of TCA showed a significant decrease in oleate oxidation within 15 minutes (Supporting Fig. S6 ), suggesting that a metabolic mechanism accounts for the impact of bile acid excess on cardiac contractility.
We examined whether deletion of FXR or its downstream target SHP could account for the changes in cardiomyocyte function in DKO mice. FXR activation is known to promote vasodilation, (48, 49) whereas loss of FXR has been implicated in protecting against myocardial apoptosis. (30) We found that FXRKO mice maintain normal cardiac function and do not exhibit metabolic changes in the heart (Supporting Fig. S4 ). Thus, loss of the bile acid sensor FXR is not the primary cause for the cardiac pathology seen in the DKO mice. On the contrary, deletion of SHP causes hypertrophy and bradycardia, along with a few changes in the metabolic gene expression pattern compared to DKO mice (Supporting Fig. S5 ). Our data validate the recently described role for SHP in regulating cardiac growth. (31) It was shown that SHP is a novel antihypertrophic regulator that acts by interfering with GATA6 signaling in the heart. (31) Further studies in cardiomyocyte-specific Fxr and Shp single and double knockouts would be necessary to fully delineate the role of the FXR-SHP axis in the heart. It is possible that TGR5, the membrane G protein-coupled bile acid receptor, (50) could mediate these responses. Further experiments will be needed to test the potential role of TGR5 in cholecardia. (50) Additionally, intraperitoneal bile acid administration reproduced the decrease in heart rate (Supporting Fig.  S6 ) in WT mice, indicating a direct role for bile acids in rhythm disturbance that does not depend on the loss of FXR or SHP function. The reduction in rhythm seen in the DKO mice is in line with clinical findings in patients with obstructive jaundice called "icteric bradycardia." (43) At the cellular level, treating HL-1 cells or neonatal cardiomyocytes with CDCA, a primary bile acid in humans, mimicked the metabolic profile of DKO hearts, including a significant down-regulation of Pgc1a and Pdk4 (Figs. 4 and 5) . Reduction in Pgc1a levels is known to be sufficient to induce a number of cardiac defects. Moreover, Pgc1a KO mice display a substrate switch from fatty acid to glucose, (33) (34) (35) which is consistent with our metabolic findings. Importantly, we have identified that these observed metabolic changes, upon bile acid overload, were rescued by restoration of Pgc1a expression (Fig. 5) . These results suggest that Pgc1a down-regulation, in response to pathologically elevated bile acid levels, is pivotal to the alteration in cardiac metabolic pathways.
Importantly, we discovered that reducing the burden of circulating bile acids with the bile acid binding resin CHR normalized the electrophysiological and functional competence of DKO hearts. These cardiac functional alterations were accompanied by increased expression of FAO genes (Pgc1a, m-Cpt1, and m-Cpt2) (Fig. 6) .
Overall, our findings define a direct role for elevated bile acid levels in altering cardiac metabolism and function. Interrupting enterohepatic circulation of bile acids and promoting their excretion using CHR or suppressing bile acid production through FXR activation could be novel potential therapeutic approaches to treat cirrhotic cardiomyopathy.
